SCHEMBL3255990

SCHEMBL3255990

CC1(C)Oc2ccc(C(=O)O)cc2O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
MAPK1 P28482 1/20 0.52
TSHR P16473 4/20 0.48
RAB9A P51151 3/20 0.44
CTNNB1 P35222 1/20 0.44
WNT3A P56704 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALOX5 P09917 1/20 0.44
RXRA P19793 1/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SRD5A2 P31213 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
TP53 P04637 1/20 0.41
CA12 O43570 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153475 0.85 KDM4E (0.50) ALDH1A1TSHRRAB9ACTNNB1WNT3A
SCHEMBL29746867 0.83 TSHR (0.53) ALDH1A1TSHRRAB9ACTNNB1WNT3A
SCHEMBL9141299 0.83 KMT2A (0.56) ALDH1A1MAPK1TSHRRAB9ANPC1
SCHEMBL11586028 0.82 ALDH1A1 (0.46) ALDH1A1MAPK1TSHRRAB9ACTNNB1
SCHEMBL8522592 0.82 RARG (0.62) ALDH1A1RAB9ATDP1RXRANPC1
SCHEMBL8522590 0.82 RARG (0.62) ALDH1A1RAB9ATDP1RXRANPC1
SCHEMBL703172 0.81 TSHR (0.45) ALDH1A1TSHRRAB9ACTNNB1WNT3A
SCHEMBL1811733 0.81 RAB9A (0.49) ALDH1A1MAPK1RAB9ATDP1ALOX5
SCHEMBL21674399 0.81 ALDH1A1 (0.52) ALDH1A1MAPK1TSHRRAB9ACTNNB1
SCHEMBL5753071 0.81 ALDH1A1 (0.52) ALDH1A1MAPK1TSHRRAB9ACTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12044968-B2 Protective film-forming composition having acetal structure and amide structure NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-12044968-B2 Protective film-forming composition having acetal structure and amide structure NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
EP-4214197-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2023-07-26 EP disclosed
WO-2023028338-A2 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
US-20220135539-A1 BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-05-05 US disclosed
WO-2022060812-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. (US) 2022-03-24 WO disclosed
US-20200409260-A1 PROTECTIVE FILM FORMING COMPOSITION HAVING AN ACETAL STRUCTURE NISSAN CHEMICAL CORPORATION (JP) 2020-12-31 US disclosed
US-20100137428-A1 OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS GLAXO GROUP LIMITED 2010-06-03 US disclosed
EP-1833811-B1 OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS GLAXO GROUP LTD (GB) 2010-06-02 EP disclosed
EP-1833811-A1 OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-09-19 EP disclosed
WO-2006067437-A1 OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed
US-4117228-A ANTIHISTAMINES EISAI CO., LTD. (JP) 1978-09-26 US disclosed
US-4083853-A ANTIHISTAMINES EISAI CO., LTD. (JA) 1978-04-11 US disclosed
US-4051125-A ANTIHISTAMINES EISAI CO., LTD. (JA) 1977-09-27 US disclosed
US-4026895-A ANTIHISTAMIC ACTIVITY EISAI CO., LTD. (JA) 1977-05-31 US disclosed
US-3981864-A ANTIHISTAMINES EISAI CO., LTD. (JA) 1976-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A ALDH1A1 3319/4885MAPK1 3337/4885TSHR 645/4885
US-20220135539-A1 BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF BRAF, NRAS, RAF1 ALDH1A1 1618/4885MAPK1 899/4885TSHR 1552/4885
US-20100137428-A1 OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS SLC18A2, SLC1A2, SLC6A3 ALDH1A1 483/4885MAPK1 2553/4885TSHR 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.